Cytosystems’ main milestones to early 2009 are as follows:

2006

• Appoint management team with extensive experience in commercialisation in biotechnology, pharmacology and life sciences
• Assemble world-class Scientific Advisory Board comprising five of the UK’s leading cancer research, oncology and renal physician experts
• Secure exclusive worldwide licence rights through to year 2018 from Cancer Research Technology (CRT) for the deployment of MCM (Mini-Chromosome Maintenance) protein antibody diagnostics in bladder cancer
• Awarded contract to the University of Aberdeen to validate the proof of principle and confirm the sensitivity and specificity of the core MCM technology over a two-year period.

2007

• Stage 1 clinical trial set up for first proof of principle  patient study in bladder cancer and completed on schedule (July 2007)
• Develop and test prototype cell collection device to process cells in urine (increases cell life from 4 hours to +15 days)
• Accredited to ISO 9001:2000
• Successful statistical analysis of initial patient cohort in bladder cancer clinical trial (achieves 95% sensitivity vs urine cytology, i.e. absence of false negative results)
• Six unique protocols researched and validated for future commercialisation, including optimum urine collection times, volume, stability, cellularity, cell integrity, antibody laboratory stability and methodology

2008

• Successfully recruited + 400 patients for Stage 2 bladder cancer clinical trial
• Patent filed for cell harvesting device
• Secure exclusive worldwide licence rights from Cancer Research Technology (CRT) for the deployment of Mini-Chromosome Maintenance protein (MCM) antibody diagnostics in prostate cancer
• Successful Proof of Concept study involving +80 prostate cancer patients at a major UK teaching hospital
• Patent applied for novel diagnosis of prostate cancer
• Set up 100-patient clinical trial for prostate cancer
• Proof of concept achieved for the digitisation, chromagenic and morphological image recognition of bladder cancer malignant against normal cells
  

2009

• Data analysis in 400-patient study confirms high sensitivity and high specificity of MCM protein antibody diagnostics compared with biopsy
• Statistical analysis of 100-patient prostate cancer clinical trial
• Undertake multi-centre patient prostate cancer study